For example, a new standard of care for patients with completely resected stage II/IIIA NSCLC is adjuvant chemotherapy followed by the PD-L1 or PD-1 blocking antibodies, atezolizumab, and pembrolizumab, respectively3,4. Here, CD274 is linked to non-small cell lung carcinoma.